HAEMATOLOGICAL NEOPLASMS are initially sensitive to chemotherapy, but the relapse
rate is usually high, except for Hodgkin's lymphoma and childhood acute lymphoblastic …

The term multidrug resistance (MDR) describes the observation that tumour cell lines can
become cross-resistant to several structurally unrelated chemotherapeutic agents after …

We have designed in vitro assays to investigate the possible association between apoptosis
and chemotherapeutic sensitivity in acute myeloid leukemias (AMLs). Consistent low levels …

An article by Breccia et al. 1 published on Leukemia highlighted one remarkable aspect of
acute promyelocytic leukemia (APL): the development of thrombosis in patients treated with …

PSC 833 (Valspodar) can reverse multidrug resistance (MDR) in patients with hematologic
malignancies, but alters the pharmacokinetics of concomitant anticancer agents. A phase I …

P-glycoprotein (Pgp) mediated multidrug resistance is often the cause of therapy failure in
some tumors. Pgp expression was shown to have prognostic value in several hematological …

Acquired drug resistance eventually leads to treatment failure in T‐cell acute lymphoblastic
leukaemia (T‐ALL). Immunophenotypic and cytogenetic heterogeneities within T‐ALL …

Multidrug resistance (MDR) is responsible for a decrease in sensitivity of tumor cells to
unrelated, naturally occurring anticancer drugs. This resistance is correlated with expression …

Two new myeloid cell lines (K051 and K052) were established from a patient with
multilineage CD7-positive acute leukemia. The K051 and K052 were established from the …

Classical approaches have been used for solving biological systems since the Newton time.
Most of the earlier effort has reduced a system to the simplest levels for the study. Such an …